Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
This article reviews the use of combination emtricitabine (FTC)/tenofovir as preexposure prophylaxis (PrEP) for HIV-negative patients at high risk of acquiring HIV, including heterosexual men and women, men who have sex with men, and IV drug users. When used with classic prevention strategies such as condoms, PrEP has been found effective in reducing the risk of HIV transmission.
Jonathan Baker practices at Laser Surgery Care and at the time this manuscript was written, was a senior physician assistant in the division of infectious diseases at the University of Pittsburgh (Pa.) Medical Center. Kevin Michael O'Hara is an assistant professor and academic coordinator of the PA program at Yale University in New Haven, Conn. Mr. O'Hara discloses that he holds stock in the biopharmaceutical companies Gilead Sciences and AbbVie. The authors have disclosed no other potential conflicts of interest, financial or otherwise.
Jonathan
J
Baker
Kevin Michael
KM
OʼHara
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D000068679:Emtricitabine / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D015994:Incidence; D008297:Male; D055118:Medication Adherence; D011634:Public Health; D012307:Risk Factors; D040242:Risk Reduction Behavior; D021841:Safe Sex; D000068698:Tenofovir / Q000008:administration & dosage*; D014481:United States / Q000453:epidemiology; D035862:Vulnerable Populations
D019380:Anti-HIV Agents; D000068698:Tenofovir; D000068679:Emtricitabine